INVIVYD, INC. Cash and Restricted Cash
INVIVYD, INC. (IVVD) had Cash and Restricted Cash of $160.08 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $160.08M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $184.15M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $226.69M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $84.97M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $160.08M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $184.15M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $226.69M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $84.97M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $34.91M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $48.08M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $69.35M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $106.87M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $147.88M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $189.39M 10-Q · filed 2025-05-15 |
| 2023-12-31 | $200.64M 10-K · filed 2026-03-05 |
| 2023-09-30 | $181.82M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $121.95M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $126.47M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $92.08M 10-K · filed 2025-03-20 |
| 2022-09-30 | $278.15M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $474.88M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $532.22M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $542.22M 10-K · filed 2024-03-28 |
| 2021-09-30 | $478.27M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $392.51M 10-Q · filed 2022-08-15 |
| 2021-03-31 | $91.25M 10-Q · filed 2022-05-13 |
| 2020-12-31 | $114.99M 8-K · filed 2024-02-09 |
| 2020-09-30 | $48.58M 10-Q · filed 2021-11-15 |
| 2020-06-02 | $0.00 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |